BofA Adjusts Price Target on MeiraGTx to $14 From $15, Maintains Buy Rating
AI Sentiment
Highly Positive
8/10
as of 01-08-2026 2:48pm EST
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 665.7M | IPO Year: | N/A |
| Target Price: | $23.83 | AVG Volume (30 days): | 462.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.11 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.55 - $9.73 | Next Earning Date: | 11-13-2025 |
| Revenue: | $27,417,000 | Revenue Growth: | 96.83% |
| Revenue Growth (this year): | -20.01% | Revenue Growth (next year): | 619.95% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
CFO & COO
Avg Cost/Share
$8.87
Shares
24,000
Total Value
$212,880.00
Owned After
829,494
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Giroux Richard | MGTX | CFO & COO | Oct 21, 2025 | Sell | $8.87 | 24,000 | $212,880.00 | 829,494 |
MGTX Breaking Stock News: Dive into MGTX Ticker-Specific Updates for Smart Investing
AI Sentiment
Highly Positive
8/10
See how MGTX stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "MGTX MeiraGTx Holdings plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.